Leading Proxy Advisory Firms Endorse Evogene's Director Nominees for Upcoming Meeting

Proxy Advisory Firms Back Evogene's Board Candidates

In a significant development for Evogene Ltd. (NASDAQ: EVGN), leading independent proxy advisory firms Institutional Shareholder Services (ISS) and Glass Lewis have recommended that shareholders vote in favor of the company's slate of highly qualified director nominees at the upcoming Annual General Meeting scheduled for September 4, 2026. This endorsement reflects the firms' assessment of the company's strategic direction and leadership.

Summary of Recommendations

The recommendations from ISS and Glass Lewis reinforce Evogene's confidence in its long-term value creation strategy. In their analyses, which were released on August 23, 2026, both advisory firms urged shareholders to support the company’s nominees and to reject the proposals made by opposition groups.

ISS noted that the dissidents' efforts to overhaul the board failed to present a credible case for change. Their message was clear: shareholders need compelling reasons to consider altering the existing management and board structure, which has shown stability and progress in recent years.

Conversely, Glass Lewis echoed this sentiment, stating that the dissenting nominees had not offered sufficiently persuasive arguments to suggest that their participation would necessarily benefit shareholders. Glass Lewis pointed out that Evogene’s board had already seen an adequate turnover, having appointed two new directors since 2021, along with a board chair who brings fresh perspectives.

Additionally, the advisory firm acknowledged the qualifications of the management's nominees, praising their relevant experience. This suggests that the current board's composition is well-suited to navigate the future challenges and opportunities within Evogene's operational sphere.

Strategic Importance of the Vote

Nir Nimrodi, Chairman of Evogene’s Board of Directors, expressed his satisfaction with the endorsements from ISS and Glass Lewis. He highlighted the confidence in the company’s strategy and the board's disciplined execution aimed at enhancing shareholder value. Nimrodi argued that the calls for change from L.I.A. Pure Capital and Invest-Pro could disrupt the company’s current momentum and strategic plans.

He declared, “We believe that the independent analysis provided by ISS and Glass Lewis reinforces our ongoing communication with shareholders that the existing board and management team are the right individuals to continue pushing Evogene's agenda forward.”

The chairman further advocated for a collective effort among shareholders to vote in favor of the nominees and other proposals that will shape the company’s direction. He emphasized, “Your vote is crucial, regardless of your shares' quantity, to protect the value of your investment in Evogene.”

Importance of Shareholder Engagement

Evogene’s management team is committed to transparency and open communications with its stakeholders. To further assist shareholders in the voting process, the company encourages any questions or requests for assistance to be directed toward their proxy solicitor, Sodali Co. The firm is readily available for any inquiries regarding the voting procedure

About Evogene Ltd.

Evogene Ltd. is a cutting-edge company specializing in computational chemistry and generative design technologies for small molecules used in pharmaceuticals and agriculture. Through innovations like ChemPass AI™, Evogene strives to revolutionize drug development and agricultural chemical solutions by leveraging advanced technologies to create novel, potent small molecules. The company pursues strategic partnerships and focuses on product development to meet the dynamic needs of the industry.

For more information about Evogene, visit www.evogene.com.

Conclusion

With ISS and Glass Lewis supporting Evogene's director nominees, shareholders are encouraged to pay close attention to the upcoming meeting. The strength of this advocacy signals a confidence in Evogene's strategic direction and its board’s capability to enhance shareholder value going forward.